Why the ALS (ASX:ALQ) share price is charging higher today

This testing services company's shares are rising today…

| More on:
A boy looks up and points his fingers to the sky in celebration pose.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The ALS Ltd (ASX: ALQ) share price is on the move on Wednesday morning.

At the time of writing, the testing services company's shares are up 3% to $12.94.

Why is the ALS share price rising?

Investors have been bidding the ALS share price higher today after the release of its annual general meeting presentation and the announcement of an acquisition.

In respect to the former, the presentation took investors through the company's performance in FY 2021 and provided an update on trading so far in FY 2022.

ALS has started FY 2022 strongly and is expecting this to lead to solid first half profit growth. Management has provided guidance of first half underlying net profit after tax of between $115 million and $125 million. The midpoint of this guidance range represents a sizeable 49% increase on the prior corresponding period.

It advised that this reflects the strong start that it is seeing across its Life Sciences and Commodities divisions as volumes continue to improve as global activity increases.

Acquisition news

Not included in its first half guidance is the proposed acquisition of an initial 49% interest in NUVISAN, a pharmaceutical testing business with operations in Germany and France.

Management believes the acquisition provides it with the platform to expand its offering from quality control testing into 'upstream' services in research and development.

Growth in this area of the market is driven by major pharmaceutical companies outsourcing drug development research and testing due to increasing pricing pressure, lack of internal capability, and expertise from external providers.

ALS will initially acquire 49% of the equity in NUVISAN for a consideration of ~EUR145 million. It also has an exclusive call option to acquire the remaining equity from 1 January 2024. This option expires by 30 September 2026 at the latest.

Should this option be exercised, the remaining 51% equity in NUVISAN will be acquired at 13x adjusted EBITDA based on the 12 months preceding the purchase.

ALS' Managing Director and CEO, Raj Naran, commented "This is a significant expansion of our Life Sciences capability as we grow our presence in the strategically important Pharmaceutical market. This will allow us to move our service offering up the supply chain into drug development and research testing, which significantly expands our addressable markets. NUVISAN offers us a platform in the key markets of Germany and France which has long been an aspiration for our Life Sciences division."

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Gainers

asx share price boosted by us investment represented by hand waving US flag across winning athlete
Best Shares

Here are the best-performing ASX 200 shares since the US election result

We reveal the 10 ASX stocks that have had the highest share price gains since the US Presidential election.

Read more »

a man sits back from his laptop computer with both hands behind his head feeling happy to see the Brambles share price moving significantly higher today
Industrials Shares

Up 39% in a year, is there more growth to come for this ASX 200 share?

IML Equity Analyst Josh Freiman shares his views on a major ASX 200 industrial stock.

Read more »

A young women pumps her fists in excitement after seeing some good news on her laptop.
Share Gainers

Why Catapult, Flight Centre, Nufarm, and Xero shares are storming higher today

These shares are having a strong session on Thursday. But why? Let's find out.

Read more »

drug capsule opening up to reveal dollar signs signifying rising asx share price
Healthcare Shares

3 ASX healthcare shares going gangbusters on Thursday

Investors are sending these ASX healthcare stocks soaring today. But why?

Read more »

A young man talks tech on his phone while looking at a laptop. A financial graph is superimposed across the image.
Share Gainers

Here are the top 10 ASX 200 shares today

The ASX 200 made it three-for-three losses in a row this Wednesday.

Read more »

A young woman wearing overalls and a yellow t-shirt kicks one leg in the air showing excitement over the latest ASX 200 shares to hit 52-week highs
Share Gainers

Why Brickworks, James Hardie, Megaport, and OFX shares are charging higher today

These shares are having a good time on hump day. But why?

Read more »

Fancy font saying top ten surrounded by gold leaf set against a dark background of glittering stars.
Share Gainers

Here are the top 10 ASX 200 shares today

ASX investors endured another day of selling this Tuesday.

Read more »

Man pointing at a blue rising share price graph.
Technology Shares

Guess which ASX 300 tech stock is already up 64% in November!

The ASX 300 tech stock is surging higher this month. But why?

Read more »